Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells $412,799.20 in Stock

Heartflow logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Heartflow insider Campbell Rogers sold 16,918 shares for $412,799.20 at an average price of $24.40, under a pre-arranged Rule 10b5-1 plan. Rogers retained 33,836 shares after the sale, reducing their ownership by 33.33%.
  • Heartflow reported quarterly revenue of $72.86 million and a loss of $0.03 per share, beating analysts’ estimate of a $0.18 loss per share. Analysts’ consensus rating was “Moderate Buy,” with a $60.12 average price target.
  • Shares fell 2.7% to $44.63 in the reported trading session. The stock’s 12-month range was $20.13 to $60.65.
  • MarketBeat previews the top five stocks to own by December 1st.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) insider Campbell Rogers sold 16,918 shares of Heartflow stock in a transaction on Friday, February 20th. The shares were sold at an average price of $24.40, for a total value of $412,799.20. Following the completion of the transaction, the insider owned 33,836 shares in the company, valued at $825,598.40. This represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

  • On Thursday, October 22nd, Campbell Rogers sold 12,157 shares of Heartflow stock. The shares were sold at an average price of $55.01, for a total value of $668,756.57.
  • On Friday, September 18th, Campbell Rogers sold 12,156 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total transaction of $609,623.40.
  • On Tuesday, November 17th, Campbell Rogers sold 12,157 shares of Heartflow stock. The shares were sold at an average price of $46.39, for a total value of $563,963.23.
  • On Tuesday, November 17th, Campbell Rogers sold 24,188 shares of Heartflow stock. The stock was sold at an average price of $46.39, for a total transaction of $1,122,081.32.
  • On Thursday, October 22nd, Campbell Rogers sold 23,933 shares of Heartflow stock. The shares were sold at an average price of $55.01, for a total transaction of $1,316,554.33.
  • On Friday, September 18th, Campbell Rogers sold 19,682 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total value of $987,052.30.

Heartflow Stock Down 2.7%

Shares of NASDAQ HTFL traded down $1.26 during midday trading on Thursday, reaching $44.63. 1,279,655 shares of the stock were exchanged, compared to its average volume of 1,615,683. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $60.65. The firm has a 50-day simple moving average of $51.84 and a two-hundred day simple moving average of $35.47. The firm has a market cap of $3.92 billion, a price-to-earnings ratio of -48.51 and a beta of 2.50.

Heartflow (NASDAQ:HTFL - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.15. Heartflow had a negative net margin of 33.11% and a negative return on equity of 20.53%. The business had revenue of $72.86 million during the quarter. During the same quarter last year, the company posted ($0.27) EPS. Research analysts expect that Heartflow, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HTFL has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Heartflow in a research report on Wednesday, November 4th. Canaccord Genuity Group lifted their price target on shares of Heartflow from $56.00 to $69.00 and gave the company a "buy" rating in a research note on Friday, November 13th. Piper Sandler reiterated an "overweight" rating and issued a $64.00 price objective (up from $45.00) on shares of Heartflow in a report on Tuesday, October 20th. JPMorgan Chase & Co. increased their price objective on Heartflow from $35.00 to $45.00 and gave the company an "overweight" rating in a research note on Friday, August 14th. Finally, Stifel Nicolaus upped their target price on shares of Heartflow from $45.00 to $70.00 and gave the stock a "buy" rating in a report on Friday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $60.12.

Get Our Latest Stock Report on Heartflow

Institutional Investors Weigh In On Heartflow

Institutional investors have recently added to or reduced their stakes in the business. XXEC Inc. purchased a new position in Heartflow during the 2nd quarter worth approximately $2,524,764,000. BlackRock Inc. purchased a new stake in Heartflow during the 2nd quarter valued at approximately $152,502,000. Bamco Inc. NY acquired a new stake in Heartflow during the 2nd quarter worth approximately $94,625,000. Jupiter Topco LLC acquired a new stake in Heartflow during the 2nd quarter worth approximately $70,983,000. Finally, Janus Henderson Group PLC grew its stake in shares of Heartflow by 152.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company's stock valued at $53,063,000 after purchasing an additional 1,315,416 shares during the last quarter.

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient's coronary arteries and provide information that can support diagnosis and treatment planning. The company's offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

Recommended Stories

Insider Buying and Selling by Quarter for Heartflow (NASDAQ:HTFL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Heartflow Right Now?

Before you consider Heartflow, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heartflow wasn't on the list.

While Heartflow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines